Home > News > Stock News > Detail
Bookmark and Share

BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3%

2018-12-07 01:21    Investing

BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3% Stock News

© Reuters. BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3%
  • Ultra-thinly traded BeyondSpring (BYSI +3.2%) is up on almost double normal volume, albeit on turnover of only 12K shares, on the heels of its announcement of positive results evaluating lead candidate Plinabulin in patients receiving docetaxel chemotherapy.
  • The study met the primary endpoint of demonstrating the non-inferiority (no worse than) of Plinabulin compared to Amgen's (AMGN -1.7%) NEULASTA (pegfilgrastim) in reducing the duration of severe neutropenia (low levels of a type of white blood cell called neutrophils) in the first cycle of chemo.
  • The company plans to file a marketing applications in China and the U.S. seeking approval for Plinabulin for the treatment of chemo-induced neutropenia.
  • The company acquired global rights to Plinabulin, a small molecule synthetic analogue of a marine microbial product, from San Diego-based Nereus Pharmaceuticals in 2013.
  • Now read: Celgene (NASDAQ:CELG): Investment Thesis Still Not Compelling


0 traders reviewed this item, please leave a reply!

About FXYEAH | Broker Listing | Contribute | Contact Us | Sitemap | TagCloud
Disclaimer: All contents of site are only for your reference, don't suggest you do any investment decision, you should be responsible for your decision.